Skip to main content
Log in

Prostatakarzinom: Radium für die Knochen

  • Literatur kompakt_Urogenitale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Viele Patienten mit metastasiertem, kastrationsresistentem Prostatakarzinom leiden unter Knochenmetastasen. Für solche Patienten scheint die Behandlung mit dem systemisch verabreichten Radionuklid Radium-223-Dichlorid eine Option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  • Sartor O et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15(7):738-46.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Willm Uwe Kampen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berndt, C., Kampen, W.U. Prostatakarzinom: Radium für die Knochen. Im Focus Onkologie 17, 32 (2014). https://doi.org/10.1007/s15015-014-1498-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1498-y

Navigation